A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd
Description
Brief Summary
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients who were
previously treated with T-DXd
Detailed Description
A Global, Single Arm, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer
Patients who were previously treated with T-DXd. The ARX788 will be administered every 3
weeks (Q3W) intravenous (IV) infusion.
Phase
N/AInclusion and Exclusion Criteria
- Age ≥ 18 years and older
- Life expectancy ≥ 6 months
- Unresectable or metastatic breast cancer subjects
- Presence of at least one measurable lesion per RECIST v 1.1
- Subjects must have an adequate tumor sample available for confirmation of HER2 status
- Subjects must have had prior treatment with no more than 5 prior regimens of systemic treatment in the metastatic setting. One of these prior treatments must have been treatment with T-DXd.
- Subjects with stable brain metastases
- Acute toxicities from any prior therapy, surgery, or radiotherapy must have resolved to Grade ≤1 as per the NCI-CTCAE v 5.0, except alopecia
- Adequate organ functions
- Willing and able to understand and sign an informed consent inform and to comply with all aspects of the protocol Key
- Any subject who meets any of the following criteria is excluded from the study:
- History of allergic reactions to any component of ARX788.
- Prior history of interstitial lung disease, pneumonitis, or other clinically significant lung disease
- Any active ocular infections or chronic corneal disorders
- History of congestive heart failure, unstable angina pectoris, unstable atrial fibrillation, or cardiac arrhythmia within 12 months prior to enrollment
- Grade 3 to 4 peripheral neuropathy (NCI CTCAE v 5.0). Patients with Grade 2 neuropathy can be enrolled at investigator's discretion
- History of unstable central nervous system (CNS) metastases
- Current severe, uncontrolled systemic disease (eg, clinically significant cardiovascular, pulmonary, or metabolic diseases)
- Any uncontrollable intercurrent illness, infection (including subjects with active, symptomatic Covid-19 infections), or other conditions that could limit study compliance or interfere with assessments
- Exposure to any other investigational or commercial anticancer agents or therapies administered with the intention to treat malignancy within 14 days before the first dose of ARX788
Sites
Please contact the trial administrator to learn more about where you can participate in this trial. Please use the contact form on the right side.
Powered by
SC CTSI